Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer
- PMID: 19778642
- DOI: 10.1016/j.bbapap.2009.09.012
Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer
Abstract
AMP-activated protein kinase (AMPK) is a cellular energy sensor activated by metabolic stresses that either inhibit ATP synthesis or accelerate ATP consumption. Activation of AMPK in response to an increase in the cellular AMP:ATP ratio results in inhibition of ATP-consuming processes such as gluconeogenesis and fatty acid synthesis, while stimulating ATP-generating processes, including fatty acid oxidation. These alterations in lipid and glucose metabolism would be expected to ameliorate the pathogenesis of obesity, type 2 diabetes and other metabolic disorders. Recently, AMPK has also been identified as a potential target for cancer prevention and/or treatment. Cell growth and proliferation are energetically demanding, and AMPK may act as an "energy checkpoint" that permits growth and proliferation only when energy reserves are sufficient. Thus, activators of AMPK could have potential as novel therapeutics both for metabolic disorders and for cancer, which together constitute two of the most prevalent groups of diseases worldwide.
Copyright 2009 Elsevier B.V. All rights reserved.
Similar articles
-
Gene of the month. AMP kinase (PRKAA1).J Clin Pathol. 2014 Sep;67(9):758-63. doi: 10.1136/jclinpath-2014-202422. J Clin Pathol. 2014. PMID: 24895169 Review.
-
Mechanisms of AMPK in the maintenance of ATP balance during energy metabolism.Cell Biol Int. 2018 Apr;42(4):384-392. doi: 10.1002/cbin.10915. Epub 2018 Jan 3. Cell Biol Int. 2018. PMID: 29205673 Review.
-
Promise and challenges for direct small molecule AMPK activators.Biochem Pharmacol. 2018 Jul;153:147-158. doi: 10.1016/j.bcp.2018.01.049. Epub 2018 Feb 3. Biochem Pharmacol. 2018. PMID: 29408352 Review.
-
Sensing of energy and nutrients by AMP-activated protein kinase.Am J Clin Nutr. 2011 Apr;93(4):891S-6. doi: 10.3945/ajcn.110.001925. Epub 2011 Feb 16. Am J Clin Nutr. 2011. PMID: 21325438 Review.
-
AMPK activators--potential therapeutics for metabolic and other diseases.Acta Physiol (Oxf). 2009 May;196(1):175-90. doi: 10.1111/j.1748-1716.2009.01967.x. Epub 2009 Feb 19. Acta Physiol (Oxf). 2009. PMID: 19245659 Review.
Cited by
-
Management of anemia of inflammation in the elderly.Anemia. 2012;2012:563251. doi: 10.1155/2012/563251. Epub 2012 Oct 3. Anemia. 2012. PMID: 23091709 Free PMC article.
-
Metformin impairs the growth of liver kinase B1-intact cervical cancer cells.Gynecol Oncol. 2012 Oct;127(1):249-55. doi: 10.1016/j.ygyno.2012.06.032. Epub 2012 Jun 24. Gynecol Oncol. 2012. PMID: 22735790 Free PMC article.
-
Snf1-related kinase inhibits colon cancer cell proliferation through calcyclin-binding protein-dependent reduction of β-catenin.FASEB J. 2012 Nov;26(11):4685-95. doi: 10.1096/fj.12-212282. Epub 2012 Aug 8. FASEB J. 2012. PMID: 22874833 Free PMC article.
-
Metabolomics identifies pyrimidine starvation as the mechanism of 5-aminoimidazole-4-carboxamide-1-β-riboside-induced apoptosis in multiple myeloma cells.Mol Cancer Ther. 2013 Jul;12(7):1310-21. doi: 10.1158/1535-7163.MCT-12-1042. Epub 2013 Apr 12. Mol Cancer Ther. 2013. PMID: 23585020 Free PMC article.
-
AMPK inhibition in health and disease.Crit Rev Biochem Mol Biol. 2010 Aug;45(4):276-95. doi: 10.3109/10409238.2010.488215. Crit Rev Biochem Mol Biol. 2010. PMID: 20522000 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical